Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC discusses novel agents, Olaparib and Rucaparib, that target BRCA mutations in Ovarian Cancer. He also states that even in patients who did not have any mutation still showed great therapeutic responses from the agents. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.
BRCA Mutation May Not be Necessary using PARP Inhibitors in Ovarian Cancer
